JATT Acquisition (JATT) Financials

Zura Bio’s latest quarter shows a very cash-rich balance sheet, but also a business that is still generating meaningful losses and burning cash. In Q1 2026, the company ended the quarter with $225.6 million in cash and equivalents and only $11.7 million in total liabilities, which gives it a solid near-term liquidity position. However, the company posted a $24.2 million net loss and used $18.9 million in operating cash during the quarter, highlighting that it remains in development-stage mode with no revenue yet.

Compared with the prior year, Zura Bio’s financial profile has changed a lot. Cash has risen sharply from $89.8 million in Q1 2024 to $225.6 million in Q1 2026, largely because of repeated equity financing. At the same time, accumulated losses have deepened, with retained earnings at negative $248.8 million. That combination is common for clinical-stage biotech companies, but it also means investors are betting heavily on future pipeline progress rather than current operating performance.

• Cash and equivalents of $225.6 million provide a substantial liquidity cushion.
• Zura Bio has no long-term debt on the latest balance sheet.
• The company generated $1.3 million in interest and investment income in Q1 2026, helping offset losses modestly.
• Operating capital appears manageable so far, with only $11.7 million in total liabilities versus $228.6 million in assets.
• Quarterly revenue remains $0, so the company is still entirely dependent on financing and future clinical success.
• Research and development spending rose to $14.7 million in Q1 2026 from $10.9 million in Q4 2025, suggesting continued pipeline investment.
• Selling, general and administrative expense also increased to $10.8 million from $7.5 million, which pushed operating costs higher.
• The company reported a $24.2 million net loss in Q1 2026, wider than the $17.2 million loss in Q4 2025.
• Operating cash burn remained significant at $18.9 million in Q1 2026.
• The latest quarter included $135.1 million of common equity issuance, showing that dilution has been a major source of funding.

Looking at the trend over the last several quarters, the key story is capital raising versus ongoing burn. Zura Bio’s cash balance surged from $89.8 million in Q1 2024 to $225.6 million in Q1 2026, but that improvement was not driven by operations. Instead, financing activities repeatedly supplied cash, while operating cash flow stayed negative every quarter provided. In other words, the company’s runway looks healthier today, but its underlying business still has not moved into self-funding territory.

From an investor standpoint, the upside case depends on clinical and development execution. The balance sheet currently buys Zura Bio time, but the company must convert that time into meaningful pipeline milestones. If operating losses continue at the current pace, future dilution could remain a risk even with the large cash position.